Holen Sie sich die Stockscreener-App
212.91
0.67%
1.42
Handel nachbörslich:
212.93
0.02
+0.01%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RMD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$211.49
Offen:
$209
24-Stunden-Volumen:
1.11M
Relative Volume:
1.09
Marktkapitalisierung:
$31.51B
Einnahmen:
$4.93B
Nettoeinkommen (Verlust:
$1.25B
KGV:
25.14
EPS:
8.47
Netto-Cashflow:
$1.38B
1W Leistung:
+1.12%
1M Leistung:
-5.26%
6M Leistung:
-11.14%
1J Leistung:
+22.48%
1-Tages-Spanne:
$202.00
$214.32
1-Wochen-Bereich:
$202.00
$217.38
52-Wochen-Spanne:
$176.33
$263.05
Resmed Inc Stock (RMD) Company Profile
Firmenname
Resmed Inc
Sektor
Telefon
(858) 746-2400
Adresse
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Vergleichen Sie RMD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
212.91 | 31.51B | 4.93B | 1.25B | 1.38B | 8.47 |
|
ISRG
Intuitive Surgical Inc
|
482.74 | 175.60B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
198.71 | 59.07B | 20.64B | 1.73B | 2.94B | 6.02 |
|
ALC
Alcon Inc
|
92.54 | 44.80B | 9.91B | 1.02B | 665.00M | 2.05 |
|
COO
The Cooper Companies, Inc.
|
79.51 | 15.75B | 3.90B | 392.30M | 288.10M | 1.95 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-19 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-01-16 | Eingeleitet | Goldman | Buy |
| 2025-01-10 | Eingeleitet | Piper Sandler | Neutral |
| 2024-12-13 | Eingeleitet | Stifel | Hold |
| 2024-09-24 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-09-18 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | Herabstufung | Needham | Buy → Hold |
| 2024-06-25 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-06-24 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-02-06 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-09-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | Hochstufung | Needham | Hold → Buy |
| 2023-09-05 | Herabstufung | UBS | Buy → Neutral |
| 2023-08-01 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | Eingeleitet | UBS | Buy |
| 2023-04-14 | Eingeleitet | Mizuho | Buy |
| 2023-01-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-10-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-10-20 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-09-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-08-15 | Herabstufung | CLSA | Buy → Outperform |
| 2022-08-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-08-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-08-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-01-31 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-01-31 | Hochstufung | Goldman | Neutral → Buy |
| 2022-01-28 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-01-13 | Hochstufung | CLSA | Outperform → Buy |
| 2022-01-13 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | Hochstufung | Macquarie | Neutral → Outperform |
| 2021-10-22 | Hochstufung | CLSA | Underperform → Outperform |
| 2021-08-02 | Herabstufung | CLSA | Outperform → Sell |
| 2021-08-02 | Herabstufung | Needham | Buy → Hold |
| 2021-07-28 | Hochstufung | Jefferies | Underperform → Hold |
| 2021-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-14 | Eingeleitet | RBC Capital Mkts | Underperform |
| 2021-06-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-06-22 | Hochstufung | Macquarie | Neutral → Outperform |
| 2021-06-22 | Eingeleitet | Robert W. Baird | Neutral |
| 2021-06-21 | Bestätigt | Needham | Buy |
| 2021-06-16 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-06-09 | Hochstufung | CLSA | Sell → Outperform |
| 2021-05-21 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-04-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-03-16 | Hochstufung | Needham | Hold → Buy |
| 2020-11-02 | Hochstufung | UBS | Neutral → Buy |
| 2020-10-30 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-10-27 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-08-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-05-01 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | Eingeleitet | CLSA | Underperform |
| 2020-01-31 | Herabstufung | UBS | Buy → Neutral |
| 2020-01-10 | Eingeleitet | Oppenheimer | Perform |
| 2019-11-22 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | Hochstufung | UBS | Neutral → Buy |
| 2019-07-16 | Herabstufung | UBS | Buy → Neutral |
| 2019-05-06 | Hochstufung | UBS | Neutral → Buy |
| 2019-04-18 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-01-25 | Herabstufung | Goldman | Buy → Neutral |
| 2019-01-25 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-10-26 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | Eingeleitet | Goldman | Buy |
Alle ansehen
Resmed Inc Aktie (RMD) Neueste Nachrichten
Fund Update: QRG CAPITAL MANAGEMENT, INC. added 47,913 shares of RESMED ($RMD) to their portfolio - Nasdaq
What Analyst Projections for Key Metrics Reveal About ResMed (RMD) Q3 Earnings - Yahoo Finance
ResMed Pushes Forward With Strong Growth In Sleep Apnea Market - Finimize
ResMed to Maintain Dominant Sleep Apnea Device Market Share, Expected to Deliver Net Cash Balance Sheet, Jarden Research Says - MarketScreener
Mizuho Securities Adjusts ResMed Price Target to $265 From $280, Maintains Outperform Rating - MarketScreener
ResMed (RMD) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Jarden Research Adjusts Resmed's Price Target to AU$39.97 from AU$41.48, Keeps at Overweight - MarketScreener
Here's Why ResMed (RMD) is a Strong Growth Stock - Yahoo
Earnings Preview: What to Expect From ResMed’s Report - TradingView
ResMed (RMD) Placed on Citi's 90-Day Downside Catalyst Watch | R - GuruFocus
Positive Outlook for Resmed Inc: Buy Rating Despite Short-Term Challenges - TipRanks
ResMed CFO Brett Sandercock sells $215,580 in stock By Investing.com - Investing.com Canada
Sonic and ResMed rejoin the Buy List - Intelligent Investor
ResMed CFO Brett Sandercock sells $215,580 in stock - Investing.com Australia
Why I'm taking a closer look at ResMed shares - The Motley Fool Australia
ResMed's Fiscal Q3 Likely to Meet Consensus Estimates; Faces Supply Chain Risks, UBS Says - MarketScreener
ResMed CEO Michael Farrell sells $1.68 million in stock By Investing.com - Investing.com India
Resmed Insider Sold Shares Worth $1,680,699, According to a Recent SEC Filing - MarketScreener
ResMed CEO Michael Farrell sells $1.68 million in stock - Investing.com
ResMed CFO Sells Shares - MarketScreener
ResMed Inc. Officer Plans to Sell Shares Under Rule 144 - TipRanks
Strength Seen in ResMed (RMD): Can Its 3.8% Jump Turn into More Strength? - Nasdaq
Resmed launches HSAT across US - HME News
ResMed Inc Chairman Emeritus Adjusts Stock Holdings - TipRanks
ResMed Inc. (RMD): A Bull Case Theory - MSN
ResMed director Peter Farrell sells $439,480 in stock By Investing.com - Investing.com South Africa
ResMed director Peter Farrell sells $439,480 in stock - Investing.com
Resmed debuts wearable, at-home sleep apnea test - Fierce Biotech
RMD Stock Benefits From the Launch of NightOwl Across US - TradingView
Should I buy Fisher & Paykel or ResMed shares? - MSN
ResMed’s global general counsel sells $14,263 in stock By Investing.com - Investing.com Canada
ResMed Launches Home Sleep Apnea Test Across US; Shares Fall 3% - MarketScreener
ResMed Inc Reports Changes in CDI and Securities Issuance - TipRanks
ResMed Inc’s General Counsel Reports Stock Transaction - TipRanks
ResMed launches at-home sleep apnea test - MassDevice
ResMed’s global general counsel sells $14,263 in stock - Investing.com India
ResMed (NYSE:RMD) Launches NightOwl Device to Simplify Home Sleep Apnea Testing Across US - Yahoo Finance
Investing in ResMed (NYSE:RMD) five years ago would have delivered you a 50% gain - simplywall.st
Resmed Launches NightOwl Home Sleep Apnea Test - Medical Product Outsourcing
Game-Changing Sleep Apnea Test: Resmed's Tiny Device Tackles 80% Diagnosis Gap - Stock Titan
Resmed To Report Third Quarter Fiscal 2025 Earnings On April 23, 2025 - MarketScreener
ResMed Director Announces Sale of Common Shares - TipRanks
Resmed to Announce Q3 Fiscal 2025 Earnings - TipRanks
Resmed Inc. (RMD): Jim Cramer Says He Likes This Sleep Apnea Treatment Stock - Insider Monkey
Resmed to Report Third Quarter Fiscal 2025 Earnings on April 23, 2025 - Bluefield Daily Telegraph
ResMed Inc. (NYSE:RMD) Stake Increased by NEOS Investment Management LLC - MarketBeat
Jim Cramer On ResMed Inc. (RMD) – “I’m With Mick! ResMed’s Doing Quite Well” - Insider Monkey
Finanzdaten der Resmed Inc-Aktie (RMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.53%
3.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):